Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIb hyperlipoproteinemia
- 1 November 1994
- journal article
- Published by Elsevier in Current Therapeutic Research
- Vol. 55 (11) , 1335-1344
- https://doi.org/10.1016/s0011-393x(05)80318-2
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusionBlood Coagulation & Fibrinolysis, 1993
- Hypertriglyceridemia and regulation of fibrinolytic activity.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects A double blind testAtherosclerosis, 1988
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988
- The triglyceride issue: A view from FraminghamAmerican Heart Journal, 1986
- The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemiaAtherosclerosis, 1986
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984
- Classification of Hyperlipidemias and HyperlipoproteinemiasCirculation, 1972